Sanatan Shreay
Overview
Explore the profile of Sanatan Shreay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Butzner M, Papademetriou E, Potluri R, Liu X, Shreay S
Am J Cardiovasc Drugs
. 2024 Aug;
24(6):801-811.
PMID: 39172207
Background: For symptomatic obstructive hypertrophic cardiomyopathy (oHCM), limited evidence exists on healthcare resource utilization (HRU) and cost for patients with symptomatic oHCM by treatment categories. We evaluated whether HRU and...
2.
Butzner M, Aronitz E, Cameron H, Tantakoun K, Shreay S, Drudge C
BMC Cardiovasc Disord
. 2024 Aug;
24(1):416.
PMID: 39127628
Background: Patients with obstructive hypertrophic cardiomyopathy (oHCM) have a substantial humanistic, clinical, and economic burden due to the array of symptoms and complications associated with the disease. The objective of...
3.
Butzner M, Kinyik-Merena C, Aguiar M, Davison N, Shreay S, Masri A
J Med Econ
. 2024 Jun;
27(1):817-825.
PMID: 38868944
Aims: Patients with obstructive hypertrophic cardiomyopathy (oHCM) experience significant clinical burden which is associated with a high economic burden. Peak oxygen uptake (pVO2), measured by cardiopulmonary exercise testing, is used...
4.
Stephens J, Brotherton S, Dunning S, Emerson L, Gilbertson D, Gitlin M, et al.
J Health Econ Outcomes Res
. 2023 Sep;
1(2):134-150.
PMID: 37662025
The costs of transporting end-stage renal disease (ESRD) patients to dialysis centers are high and growing rapidly. Research has suggested that substantial cost savings could be achieved if medically appropriate...
5.
Romero-Gomez M, Kachru N, Zamorano M, Darba J, Shreay S
Medicine (Baltimore)
. 2020 Dec;
99(50):e23506.
PMID: 33327291
The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) presents many public health challenges, including a substantial impact on healthcare resource utilization and costs. There are...
6.
Ghia P, Coutre S, Cheson B, Barrientos J, Hillmen P, Pettitt A, et al.
Haematologica
. 2020 Oct;
105(10):e519.
PMID: 33054096
No abstract available.
7.
Das M, Ting J, Shreay S, Bush S
Ann Intern Med
. 2020 Sep;
173(6):506-507.
PMID: 32926826
No abstract available.
8.
Boursier J, Shreay S, Fabron C, Torreton E, Fraysse J
EClinicalMedicine
. 2020 Aug;
25:100445.
PMID: 32775971
Background: Nonalcoholic fatty liver disease (NAFLD) has reached high prevalence, paralleling the obesity pandemic. The aggressive form of the disease, nonalcoholic steatohepatitis (NASH), is characterized by fatty infiltration and inflammation...
9.
Loomba R, Wong R, Fraysse J, Shreay S, Li S, Harrison S, et al.
Aliment Pharmacol Ther
. 2020 May;
51(11):1200-1201.
PMID: 32424927
No abstract available.
10.
Petta S, Ting J, Saragoni S, Degli Esposti L, Shreay S, Petroni M, et al.
Nutr Metab Cardiovasc Dis
. 2020 May;
30(6):1014-1022.
PMID: 32423665
Background And Aims: Nonalcoholic steatohepatitis (NASH) may progress to advanced liver disease (AdvLD). This study characterized comorbidities, healthcare resource utilization (HCRU) and associated costs among hospitalized patients with AdvLD due...